Blockchain Registration Transaction Record

VolitionRx's Liquid Biopsy Shows 95% Accuracy in Early Cancer Detection

VolitionRx announces 95% accurate liquid biopsy for early cancer detection using Capture-Seq technology. Study shows 94-96% detection rates for stage I-II cancers targeting $36B market.

This development represents a potential paradigm shift in cancer screening and early detection. Liquid biopsies like VolitionRx's Capture-Seq technology could make cancer detection more accessible, less invasive, and potentially more affordable than traditional methods like imaging scans or tissue biopsies. Early detection is crucial in cancer treatment—cancers caught at stage I or II typically have dramatically better survival rates and treatment outcomes than those detected later. For patients, this could mean earlier interventions, less aggressive treatments, and significantly improved quality of life. For healthcare systems, widespread adoption of such technology could reduce late-stage cancer treatment costs and improve population health outcomes. The technology's potential applications in multi-cancer early detection and minimal residual disease monitoring could transform how we approach cancer surveillance and treatment response assessment.